Thursday, 15 October 2026European Markets

BOUVET, NEURONES, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Information Technology Services Industry.

Loading stream...

(vianews) - bouvet (bouv.ol) is among this list of stock assets with the highest dividend rate and return on equity on the information technology services industry.

financial asset price forward dividend yield return on equity
bouvet (bouv.ol) kr64.80 4.08% 60.9%
neurones (nro.pa) €45.80 2.53% 14.95%
novabase,sgps (nba.ls) €7.40 2.26% 14.03%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bouvet (bouv.ol)

4.08% forward dividend yield and 60.9% return on equity

bouvet asa provides it and digital communication consultancy services for public and private sector companies in norway, sweden, and internationally. the company was incorporated in 1995 and is headquartered in oslo, norway.

earnings per share

as for profitability, bouvet has a trailing twelve months eps of kr3.14.

pe ratio

bouvet has a trailing twelve months price to earnings ratio of 20.64. meaning, the purchaser of the share is investing kr20.64 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.9%.

volatility

bouvet's last week, last month's, and last quarter's current intraday variation average was 1.25%, 0.96%, and 1.27%.

bouvet's highest amplitude of average volatility was 1.25% (last week), 1.23% (last month), and 1.27% (last quarter).

volume

today's last reported volume for bouvet is 21490 which is 48.28% below its average volume of 41554.

moving average

bouvet's worth is above its 50-day moving average of kr63.78 and above its 200-day moving average of kr62.05.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, bouvet's stock is considered to be oversold (<=20).

more news about bouvet.

2. neurones (nro.pa)

2.53% forward dividend yield and 14.95% return on equity

neurones s.a., an information technology (it) services company, provides infrastructure, application, and consulting services in france and internationally. its infrastructure services include infrastructure management, manages public and private cloud services, it operations, user support, devops, cybersecurity, it service management, information system governance, and automation. the company also provides application services in the areas of sap, digital, web, mobility, ux/ui, enterprise content and document management, business process management, robotic process automation, dematerialization, it consulting for finance, big data, and devops, it training and change management, and innovation connected devices (iot). in addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, devops, ci/cd, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, ux/ui, and digital marketing, as well as internal process digitization, ecm/bpm, rpa, dematerialization, ai, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. the company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. neurones s.a. was founded in 1984 and is based in nanterre, france.

earnings per share

as for profitability, neurones has a trailing twelve months eps of €1.96.

pe ratio

neurones has a trailing twelve months price to earnings ratio of 23.37. meaning, the purchaser of the share is investing €23.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.95%.

more news about neurones.

3. novabase,sgps (nba.ls)

2.26% forward dividend yield and 14.03% return on equity

novabase s.g.p.s., s.a., through its subsidiaries, provides it consulting and services in portugal, rest of europe, africa, the middle east, and internationally. it operates through two segments, next-gen and value portfolio. the next-gen segment develops it consulting and services to banks, insurance, capital markets, and telecommunication industries under the celfocus brand name. the value portfolio segment is involved in venture capital activities. novabase s.g.p.s., s.a. was incorporated in 1989 and is headquartered in lisbon, portugal.

earnings per share

as for profitability, novabase,sgps has a trailing twelve months eps of €0.11.

pe ratio

novabase,sgps has a trailing twelve months price to earnings ratio of 67.27. meaning, the purchaser of the share is investing €67.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.

volatility

novabase,sgps's last week, last month's, and last quarter's current intraday variation average was 1.03%, 1.05%, and 1.73%.

novabase,sgps's highest amplitude of average volatility was 1.71% (last week), 1.68% (last month), and 1.73% (last quarter).

moving average

novabase,sgps's value is way higher than its 50-day moving average of €4.62 and way higher than its 200-day moving average of €4.68.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, novabase,sgps's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth grew by 16.9%, now sitting on 176.23m for the twelve trailing months.

more news about novabase,sgps.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com